Clopivas tablets are utilized to prevent blood clot formation (thrombosis) in order to lower the likelihood of heart attacks (myocardial infarctions) or strokes in individuals with cardiovascular issues, those recovering from a recent heart attack or stroke, or those with known peripheral artery disease (poor leg circulation due to blocked arteries). Additionally, it is used to treat individuals experiencing unstable angina (chest pain) who are at risk of having a heart attack and may be prescribed alongside aspirin, another anticoagulant.
Clopivas contains Clopidogrel, a highly efficient and targeted inhibitor of platelet aggregation (clumping), which is a crucial step in the blood clotting (thrombosis) process to seal a damaged blood vessel and halt bleeding. Platelets can also be prompted to clump when they encounter a ruptured atherosclerotic plaque (hardened artery wall due to cholesterol accumulation), which can lead to blood clots that may obstruct arteries, interrupting blood flow to different body parts. If blockage occurs in the coronary arteries (which supply blood to the heart), it can result in an oxygen deficiency, potentially triggering a heart attack; similarly, blockage in arteries leading to the brain can lead to oxygen deprivation, resulting in a stroke.
The Clopidogrel in Clopivas inhibits the attachment of a chemical known as adenosine diphosphate (ADP) to its receptor on platelets, a process that activates platelets to aggregate. This mechanism promotes uninterrupted blood circulation and diminishes the risk of blood clot formation in individuals suffering from cardiovascular diseases and who are vulnerable to heart attacks or strokes.
Possible side effects include: abdominal discomfort, dyspepsia (indigestion), diarrhea, constipation, more frequent bleeding or bruising, prolonged bleeding time, gastrointestinal hemorrhage, fatigue, skin rash, itching, neutropenia, palpitations, fainting, weakness, neuralgia, paresthesia (numbness or tingling), and dizziness.